The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Powerful CAR-T duo uses artificial ‘claws’ to grab and destroy HIV

| | August 23, 2019

Lengtigen, a biotech company based in Gaithersburg, MD, teamed up with researchers at the Albert Einstein College of Medicine in New York to dust off a blue-sky idea inspired by people who naturally fight off HIV. What if there’s a way to recreate super-powered immune cells in the lab? And what if we could do this using the patient’s own immune cells to prevent rejection?

Described in Science Translational Medicine, the team engineered super-immune T cells that are not only resistant to HIV infection, but that can also efficiently hunt down strains widely different in their genetic makeup, including those that normally escape other treatments. Inspired by cancer CAR-T, the team engineered two artificial “claws” onto natural T cells that grab onto the surface of HIV in a death grip. In mice injected with HIV-infected human cells, the amped-up duo CAR-T cells suppressed the virus by 97 percent in their spleens—normally a sanctuary for the HIV virus to regroup and bide its time.

“CAR-T cells are making massive advances in cancer, so there’s a huge rationale to expanding their use in the HIV cure effort,” [researcher Steven Deeks] said.

Read full, original post: This CAR-T Tag-Team Could Wipe Out HIV for Good

Related article:  3D printed organs: We're closer to solving the problem of how to supply them with blood
The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend